Mr. Mallon was appointed to be the NeoGenomics Chief Executive Officer and Member of the Board of Directors, effective April 19, 2021. Mark Mallon has had a long and distinguished career in health care. Prior to serving as CEO of Ironwood Pharmaceuticals, where he led the financial transformation of the company to profitability and significantly accelerated the growth of its commercial product, Mr. Mallon spent twenty-four years at AstraZeneca, where he had a strong track record of success building industry-leading businesses in the U.S. and globally. Mr. Mallon served on the executive committee as Executive Vice President of Global Product and Portfolio Strategy, leading global marketing, pricing and market access, medical affairs (including health economics and real-world evidence), and corporate affairs. He also co-chaired the Late-Stage Product Development Committee for AstraZeneca’s $18 billion Bio-Pharmaceutical business, and, prior to that role, led AstraZeneca’s International Region, where he managed a high-growth $6.5 billion business with over 20,000 employees. He launched AstraZeneca’s emerging market strategy and led the expansion and growth of the Company’s business in China, where it was the second-fastest growing major multinational and second-largest pharmaceutical company. As EVP of International, he also oversaw $800 million of Oncology sales spanning more than 50 countries. As President of AstraZeneca China, Chief Operating Officer of AstraZeneca Japan, Vice President of U.S. Sales and Marketing Operations and President of AstraZeneca Italy, Mr. Mallon delivered several best-in-class new product launches, including immunotherapy and targeted therapeutics. Mr. Mallon holds a B.S. in Chemical Engineering from the University of Pennsylvania and an M.B.A. in Marketing and Finance from the Wharton School of Business.